Información de BioMarin Pharmaceutical Inc, dividendo de BioMarin Pharmaceutical Inc, actividades de los accionistas y más

Más Datos de BioMarin Pharmaceutical Inc Compañía

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Información de BioMarin Pharmaceutical Inc



Símbolo de cotizaciónBMRN

Nombre de la empresaBioMarin Pharmaceutical Inc

Fecha de salida a bolsaJul 23, 1999

Director ejecutivoHardy (Alexander)

Número de empleados3040

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 23

Dirección770 Lindaro Street

CiudadSAN RAFAEL

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal94901

Teléfono14155066700

Sitio Webhttps://www.biomarin.com/

Símbolo de cotizaciónBMRN

Fecha de salida a bolsaJul 23, 1999

Director ejecutivoHardy (Alexander)

Ejecutivos de BioMarin Pharmaceutical Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+6650.00%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-16570.00%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-3304.00%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+6650.00%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-2428.00%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+6650.00%

Ms. Barbara W. Bodem

Independent Director

8.83K

+6650.00%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+6650.00%

Mr. G. Eric Davis

Executive Vice President, Secretary, Chief Legal Officer

--

Mr. Brian R. Mueller, CPA

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+6650.00%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-16570.00%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-3304.00%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+6650.00%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-2428.00%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+6650.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Voxzogo

218.39M

28.70%

Vimizim

182.75M

24.02%

Naglazyme

122.03M

16.04%

Palynziq

108.78M

14.30%

Aldurazyme

53.71M

7.06%

Otro

75.16M

9.88%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

274.11M

36.03%

Europe

195.18M

25.65%

Rest of the world

140.19M

18.43%

Latin America

97.62M

12.83%

ALDURAZYME net product revenues marked by Sanofi

53.71M

7.06%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Voxzogo

218.39M

28.70%

Vimizim

182.75M

24.02%

Naglazyme

122.03M

16.04%

Palynziq

108.78M

14.30%

Aldurazyme

53.71M

7.06%

Otro

75.16M

9.88%

Estadísticas de accionistas

Actualizado: vie., 6 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.41%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

Otro

61.48%

Accionistas

Proporción

The Vanguard Group, Inc.

9.41%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

Otro

61.48%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

46.62%

Investment Advisor/Hedge Fund

37.53%

Hedge Fund

6.69%

Pension Fund

3.03%

Sovereign Wealth Fund

1.40%

Research Firm

1.35%

Individual Investor

0.74%

Bank and Trust

0.67%

Venture Capital

0.35%

Otro

1.62%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

1342

187.67M

97.68%

-21.49M

2025Q3

1334

187.86M

111.13%

-2.15M

2025Q2

1344

190.17M

114.04%

-8.63M

2025Q1

1331

198.83M

113.78%

-19.35M

2024Q4

1317

196.49M

110.91%

+4.70M

2024Q3

1283

191.71M

111.61%

-4.43M

2024Q2

1271

195.66M

108.22%

+2.33M

2024Q1

1257

193.46M

109.63%

-14.58M

2023Q4

1275

195.75M

103.93%

+7.49M

2023Q3

1255

188.56M

102.57%

+2.75M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

18.49M

9.63%

-419.17K

-2.22%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

17.25M

8.98%

-790.94K

-4.38%

Sep 30, 2025

PRIMECAP Management Company

15.23M

7.93%

-542.89K

-3.44%

Sep 30, 2025

Dodge & Cox

14.69M

7.64%

-421.51K

-2.79%

Sep 30, 2025

State Street Investment Management (US)

8.76M

4.56%

-83.15K

-0.94%

Sep 30, 2025

Viking Global Investors LP

8.32M

4.33%

-3.97M

-32.28%

Sep 30, 2025

AQR Capital Management, LLC

5.93M

3.09%

+351.54K

+6.30%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.54M

1.84%

+67.68K

+1.95%

Sep 30, 2025

Rothschild & Co Asset Management Europe SCS

2.63M

1.37%

+317.58K

+13.74%

Nov 30, 2025

Millennium Management LLC

2.63M

1.37%

-207.15K

-7.31%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

First Trust NYSE Arca Biotechnology Index Fund

3.44%

Global X Genomics & Biotechnology ETF

2.98%

Invesco Biotechnology & Genome ETF

2.47%

First Trust Health Care Alphadex Fund

2.15%

Goldman Sachs Future Health Care Equity ETF

2.15%

State Street SPDR S&P Biotech ETF

1.93%

WealthTrust DBS Long Term Growth ETF

1.86%

Alger Russell Innovation ETF

1.84%

Virtus LifeSci Biotech Products ETF

1.5%

VanEck Biotech ETF

1.4%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.44%

Global X Genomics & Biotechnology ETF

Proporción2.98%

Invesco Biotechnology & Genome ETF

Proporción2.47%

First Trust Health Care Alphadex Fund

Proporción2.15%

Goldman Sachs Future Health Care Equity ETF

Proporción2.15%

State Street SPDR S&P Biotech ETF

Proporción1.93%

WealthTrust DBS Long Term Growth ETF

Proporción1.86%

Alger Russell Innovation ETF

Proporción1.84%

Virtus LifeSci Biotech Products ETF

Proporción1.5%

VanEck Biotech ETF

Proporción1.4%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos